Safinamide
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 133865-89-1  202825-46-5 (mesylate) |
| ATC code | None |
| PubChem | CID 131682 |
| ChemSpider | 116349  |
| UNII | 90ENL74SIG |
| ChEMBL | CHEMBL396778 |
| Synonyms | (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl] methylamino]propanamide |
| Chemical data | |
| Formula | C17H19FN2O2 |
| Mol. mass | 302.34 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Safinamide (EMD 1195686) is a candidate drug against Parkinson's disease with multiple methods of action.[1] In 2007, a Phase III clinical trial was started. It is scheduled to run until 2011.[2] The compound was originally developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.[3]
Potential additional uses might be restless legs syndrome (RLS) and epilepsy.[4] They were being tested in Phase II trials in 2008, but no results are available.
[edit] Methods of action
[edit] Parkinson and RLS relevant mechanisms
Safinamide is a monoamine oxidase B inhibitor, reducing degradation of dopamine, and a glutamate release inhibitor.[5] It also seems to inhibit dopamine reuptake.[6] Additionally, safinamide blocks sodium and calcium channels.[5]
[edit] References
- ^ Fariello, RG (2007). "Safinamide". Neurotherapeutics 4 (1): 110–116. doi:10.1016/j.nurt.2006.11.011. PMID 17199024.
- ^ Study of Safinamide in Early Parkinson's Disease as Add-on to Dopamine Agonist (MOTION)
- ^ Merck Returns Rights for Safinamide to Newron, 21 October 2011.
- ^ Chazot, PL (2007). "Drug evaluation: Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome". Current opinion in investigational drugs 8 (7): 570–579. PMID 17659477.
- ^ a b Caccia, C; Maj, R; Calabresi, M; Maestroni, S; Faravelli, L; Curatolo, L; Salvati, P; Fariello, RG (2006). "Safinamide: From molecular targets to a new anti-Parkinson drug". Neurology 67 (7 Suppl 2): S18–23. PMID 17030736.
- ^ Merck Serono: Vielversprechende Daten zur kognitiven Wirkung von Safinamid bei Parkinson im Frühstadium. (German) 8 June 2007.
|
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
